Benzinga's Top #PreMarket Gainers

shares climbed 23.46 percent to $4.00 in pre-market trading after the company announced that it is moving forward with the development program for ANAVEX 2-7.

shares surged 8.11 percent to $19.33 in pre-market trading following announcement of

$20.00 per share offer.

shares rose 5.78 percent to $92.00 in pre-market trading following

announcement of details of offer.

gained 5.14 percent to $83.70 in pre-market trading. Goldman Sachs initiated coverage on bluebird bio with a Buy rating and a $165.00 price target.

shares rose 2.25 percent to $74.49 in pre-market trading after the company reported stronger-than-expected results for the third quarter.